X4 Pharmaceuticals, Inc (XFOR) SEC filings

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30

$3.12−0.05 (-1.58%)

Close on Nov 13, 2026Market cap $309.34MP/E –Yield –

SEC filings

40 of X4 Pharmaceuticals's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Oct 29, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Oct 7, 2026	Oct 8, 2026	SEC EDGAR
Current report	8-K	Sep 8, 2026	Sep 9, 2026	SEC EDGAR
Current report	8-K	Sep 8, 2026	Sep 8, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 30, 2026	Jul 1, 2026	SEC EDGAR
Current report	8-K	May 11, 2026	May 12, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 6, 2026	SEC EDGAR
Proxy statement	DEF 14A	Mar 20, 2026	Mar 20, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 17, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Nov 5, 2025	Nov 5, 2025	SEC EDGAR
Current report	8-K	Oct 23, 2025	Oct 27, 2025	SEC EDGAR
Current report	8-K	Sep 15, 2025	Sep 17, 2025	SEC EDGAR
Current report	8-K	Aug 22, 2025	Aug 25, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Aug 11, 2025	Aug 12, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 8, 2025	SEC EDGAR
Current report	8-K	Jun 23, 2025	Jun 23, 2025	SEC EDGAR
Current report	8-K	Jun 11, 2025	Jun 11, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 1, 2025	SEC EDGAR
Current report	8-K	May 1, 2025	May 1, 2025	SEC EDGAR
Proxy statement	DEF 14A	Apr 25, 2025	Apr 25, 2025	SEC EDGAR
Current report	8-K	Apr 24, 2025	Apr 24, 2025	SEC EDGAR
Current report	8-K	Apr 17, 2025	Apr 18, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 26, 2025	SEC EDGAR
Current report	8-K	Mar 25, 2025	Mar 25, 2025	SEC EDGAR
Proxy statement	DEF 14A	Mar 24, 2025	Mar 24, 2025	SEC EDGAR
Current report	8-K	Mar 3, 2025	Mar 3, 2025	SEC EDGAR
Current report	8-K	Feb 6, 2025	Feb 6, 2025	SEC EDGAR
Current report	8-K	Jan 13, 2025	Jan 13, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 13, 2024	SEC EDGAR
Current report	8-K	Nov 13, 2024	Nov 13, 2024	SEC EDGAR
Current report	8-K	Nov 13, 2024	Nov 13, 2024	SEC EDGAR
Current report	8-K	Aug 13, 2024	Aug 16, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 9, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Jul 19, 2024	Jul 19, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in X4 Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-30 reverse split on Apr 28, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is XFOR.

Compare: XFOR vs CRBU · XFOR vs RLAY · XFOR vs ELOX · XFOR vs CRSP · XFOR vs IPHA

Revenue growth73.7% · median 1.6%

Operating margin-812.0% · median -2114.8%

Net margin-813.3% · median -1812.1%

Company	Revenue	Growth
CRSP	$25.17M	-34.3%
RLAY	$10.35M	+23.9%
XFOR	$9.90M	+73.7%
CRBU	$9.44M	+1.6%
ELOX	–	–
IPHA	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 45
Held by institutions: 100.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1501697

Advertisement
300 × 250

See a number that looks wrong?